Zainul-Abideen Syed, MD
Gastroenterology · Gloversville, NYNPI 1366528523
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 132 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 15 manufacturers reported payments, led by AbbVie at 55.4% of the total. 2025 is the largest year on record at $1,143, 8.3 times the $138 reported in 2019.
Across 132 payments — averaging $20.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Johnson & Johnson$589
- Gilead$174
- Sanofi$88
- Takeda Pharmaceuticals U.S.A., Inc.$80
- Ardelyx, Inc.$68
- plus $199 from 9 others
What the payments were for
- Food & beverage$2,687100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 78 | $1,488 |
| Johnson & Johnson | 24 | $589 |
| Gilead | 9 | $174 |
| Sanofi | 3 | $88 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $80 |
| Ardelyx, Inc. | 3 | $68 |
| Intercept Pharmaceuticals, Inc. | 3 | $54 |
| Ipsen Biopharmaceuticals, Inc | 1 | $27 |
| Exact Sciences | 1 | $24 |
| Acell, Inc. | 1 | $20 |
| Lilly USA, LLC | 1 | $17 |
| Bristol Myers Squibb | 1 | $15 |
| Pfizer | 1 | $15 |
| Celltrion USA Inc. | 1 | $15 |
| Ironwood Pharmaceuticals, Inc | 1 | $11 |
How this compares
$2,687 in reported general payments places this provider in the 55th percentile of 1,682 gastroenterology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Mesalamine ErMesalamine | 13 | $6,239 |
| Famotidine | 26 | $1,794 |
| Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates | 19 | $1,103 |
| Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl | 72 | $1,042 |
| Omeprazole | 97 | $915 |
| Esomeprazole Magnesium | 14 | $884 |
| Peg-3350 And ElectrolytesPeg3350/Sod Sulf,bicarb,cl/Kcl | 51 | $812 |
| Peg 3350-ElectrolyteSodium Chloride/Nahco3/Kcl/Peg | 17 | $410 |
Paid to pharmacies, not to this prescriber.
Other gastroenterology in Gloversville
- David Carr LockeNew York$2M
- Arthur KornbluthNew York$1.9M
- Maya SrivastavaWilliamsville$1.8M
- Melissa PalmerPlainview$1M
- Sonal KumarNew York$1M
- David PoppersNew York$939K
- Ellen ScherlNew York$857K
- Bruce SandsNew York$810K
- Jean Frederick ColombelNew York$786K
- Seth GrossNew York$624K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.